![Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension | Nature Medicine Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-020-1037-7/MediaObjects/41591_2020_1037_Fig1_HTML.png)
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension | Nature Medicine
![Design and Conduct Considerations for First‐in‐Human Trials - Shen - 2019 - Clinical and Translational Science - Wiley Online Library Design and Conduct Considerations for First‐in‐Human Trials - Shen - 2019 - Clinical and Translational Science - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/c4f2ebb5-e61c-4999-8e35-18c7e431793d/cts12582-fig-0001-m.jpg)
Design and Conduct Considerations for First‐in‐Human Trials - Shen - 2019 - Clinical and Translational Science - Wiley Online Library
![EMA publishes revised guidelines to reduce risk in first-in-human clinical trials - The Pharmaceutical Journal EMA publishes revised guidelines to reduce risk in first-in-human clinical trials - The Pharmaceutical Journal](https://pharmaceutical-journal.com/wp-content/uploads/2021/01/trial-volunteers-ss-17-927x617.jpg)
EMA publishes revised guidelines to reduce risk in first-in-human clinical trials - The Pharmaceutical Journal
![Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible? | Journal of Nuclear Medicine Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible? | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/60/2/158/F1.large.jpg?width=800&height=600&carousel=1)
Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible? | Journal of Nuclear Medicine
![Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study - The Lancet Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c64c0430-8a6c-429a-a3a0-4e4afdc34f46/gr1_lrg.jpg)
Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study - The Lancet
![Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials - Cytotherapy Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials - Cytotherapy](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/3c800e1f-a88f-4c22-8557-6a58c030d7c1/gr1.jpg)
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials - Cytotherapy
![Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible? | Journal of Nuclear Medicine Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible? | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/60/2/158/F2.large.jpg)
Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible? | Journal of Nuclear Medicine
![Early phase clinical trials extension to guidelines for the content of statistical analysis plans | The BMJ Early phase clinical trials extension to guidelines for the content of statistical analysis plans | The BMJ](https://www.bmj.com/content/bmj/376/bmj-2021-068177/F1.medium.jpg)
Early phase clinical trials extension to guidelines for the content of statistical analysis plans | The BMJ
![FDA draft guidance aims to expedite first-in-human clinical trials for oncology drugs and biologics - Pearl Pathways FDA draft guidance aims to expedite first-in-human clinical trials for oncology drugs and biologics - Pearl Pathways](https://i0.wp.com/www.pearlpathways.com/wp-content/uploads/2018/03/patient_care_irb.jpg?fit=1800%2C1200&ssl=1)